Impact Analysis of Covid-19

The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Diabetes is characterized by high presence of blood glucose, also called blood sugar, in the body. There are three main types of diabetes: type 1, type 2, and gestational diabetes. Oral glucose tolerance testing and hemoglobin A1c (HbA1c) testing are some of the tests used in the diagnosis of the chronic condition. Metformin, Sulfonylureas, Meglitinides, Thiazolidinediones, and Dipeptidyl peptidase-4 (DPP-4) inhibitors are some of the therapies used for the treatment of diabetes.

The global diabetes devices and drugs (diagnosis, monitoring, and therapeutics) market is estimated to account for US$ 118,955.0 Mn in terms of value in 2020 and is expected to reach US$ 231,909.8 Mn by the end of 2027.

Global Diabetes Devices and Drugs (Diagnosis, Monitoring, and Therapeutics) Market: Drivers

Increasing prevalence of diabetes is expected to propel growth of the global diabetes devices and drugs (diagnosis, monitoring, and therapeutics) market over the forecast period. For instance, according to the study, “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition”, published in the journal Diabetes Research and Clinical Practice, in September 2019, 463 million people are expected to suffer from diabetes in 2019 worldwide and the number is expected to reach 578 million by 2030 and 700 million by 2045.

Moreover, high incidence of obesity is also expected to aid in growth of the market. For instance, according to the Centers of Disease Control and Prevention, Behavioral Risk Factor Surveillance System, 2018, 71424.3 thousand people in the U.S. suffer from obesity.     

Therapeutics held dominant position in the global diabetes devices and drugs (diagnosis, monitoring, and therapeutics) market in 2019, accounting for 74.1% share in terms of value, followed by diagnosis & monitoring.

Figure 1. Global Diabetes Devices and Drugs (Diagnosis, Monitoring, and Therapeutics) Market Share (%) Value , by Category, 2019

Diabetes Devices and Drugs (Diagnosis, Monitoring, and Therapeutics)  | Coherent Market Insights

Global Diabetes Devices and Drugs (Diagnosis, Monitoring, and Therapeutics) Market: Restraints

Lack of awareness about diabetes diagnostics and treatment, especially in emerging economies, is expected to hinder growth of the global diabetes devices and drugs (diagnosis, monitoring, and therapeutics) market. The disease was considered common in older adults. However, the condition has spread among children and adolescents. According to the American Diabetes Association, in 2018, 7.3 million were undiagnosed with diabetes in the U.S.

Moreover, recall of diabetes drugs is also expected to limit growth of the market. For instance, in March 2020, JAMP Pharma Corporation voluntarily recalled Metformin, an anti-diabetic medication, from the Canadian market, owing to potential presence of nitrosamine impurities in the finished product.

Global Diabetes Devices and Drugs (Diagnosis, Monitoring, and Therapeutics) Market: Opportunities 

Increasing prevalence of diabetes in emerging economies is expected to offer lucrative growth opportunities for players in the market. For instance, according to the National Diabetes and Diabetic Retinopathy Survey report released Government of India, in October 2019, the prevalence of known diabetes cases was 8.0% and new diabetes cases was 3.8% in India during 2015-2019.

Moreover, R&D in diabetes is also expected to aid in growth of the market. For instance, in April 2020, researchers from University of Messina, Italy, reported that measurement of Band 3 protein anion exchange capability can aid in monitoring the impact of hyperglycemia on erythrocytes homeostasis.

The global diabetes devices and drugs (diagnosis, monitoring, and therapeutics) market was valued at US$ 108,190.4 Mn in 2019 and is forecast to reach a value of US$ 231,909.8 Mn by 2027 at a CAGR of 10.0% between 2020 and 2027.

Figure 2. Global Diabetes Devices and Drugs (Diagnosis, Monitoring, and Therapeutics) Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

Diabetes Devices and Drugs (Diagnosis, Monitoring, and Therapeutics)  | Coherent Market Insights

Market Trends/Key Takeaways

In the U.S., the economic burden of diabetes is high. For instance, according to the study, ‘The Economic Burden of Elevated Blood Glucose Levels in 2017: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes, and Prediabetes’, published in the journal Diabetes Care, in April 2019, the economic burden associated with diagnosed diabetes, undiagnosed diabetes, prediabetes (adults), and gestational diabetes (mothers and newborns) reached US$ 327.2 billion, US$ 31.7 billion, US$ 43.4 billion for prediabetes, and US$ 1.6 billion for gestational diabetes, respectively, in 2017, in the U.S.

Development of novel approaches in administering insulin is expected to aid in growth of the market. For instance, in April 2020, researchers from Universidade de Lisboa, Portugal, reported that coating of insulin-loaded nanoparticles with chitosan can enhance peroral delivery of insulin.

Global Diabetes Devices and Drugs (Diagnosis, Monitoring, and Therapeutics) Market: Competitive Landscape

Major players operating in the global diabetes devices and drugs (diagnosis, monitoring, and therapeutics) market include, Abbott Laboratories, Bristol-Myers Squibb, DexCom, Inc., Eli Lilly and Company, Companion Medical, GlaxoSmithKline plc, Glenmark Pharmaceuticals, Johnson & Johnson, Lupin Ltd., F. Hoffmann-La Roche AG, and Sanofi.

Global Diabetes Devices and Drugs (Diagnosis, Monitoring, and Therapeutics) Market: Key Developments

Major players in the market are focused on launching new products to expand their product portfolio. For instance, in April 2020, Companion Medical launched the new version of the InPen app, which offers a fixed dose and meal estimation dose calculator for people with Type 1 or Type 2 insulin-dependent diabetes.

Similarly, in March 2020, Nemaura Medical Inc. announced to launch proBEAT, a digital healthcare subscription service that aids in management of pre-diabetic and Type 2 diabetics, in the U.S.

Diabetes devices and drugs (diagnosis, monitoring and therapeutics) consists of diabetes management right from diagnosis, monitoring, till treatment. Diabetes is characterized by high presence of blood glucose, also called blood sugar, in the body. There are three main types of diabetes: type 1, type 2, and gestational diabetes. Oral glucose tolerance testing and hemoglobin A1c (HbA1c) testing are some of the tests used in the diagnosis of the chronic condition. Treatment options include use of insulin, oral hypoglycemic agents, and others.   

Restraints of the Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market

Lack of awareness about diabetes diagnostics and treatment, especially in emerging economies, is expected to hinder growth of the global diabetes devices and drugs (diagnosis, monitoring, and therapeutics) market. Moreover, recall of diabetes drugs is also expected to limit growth of the market.

Key features of the study:

  • This report provides in-depth analysis of the global diabetes devices and drugs (diagnosis, monitoring and therapeutics) market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020–2027), considering 2019, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global diabetes devices and drugs (diagnosis, monitoring and therapeutics) market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Abbott Laboratories, Bristol-Myers Squibb, DexCom, Inc., Eli Lilly and Company, Companion Medical, GlaxoSmithKline plc, Glenmark Pharmaceuticals, Johnson & Johnson, Lupin Ltd., F. Hoffmann-La Roche AG, and Sanofi.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global diabetes devices and drugs (diagnosis, monitoring and therapeutics) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market, By Category:
    • Diagnosis and Monitoring
      • Blood Glucose Monitoring Devices
      • Other Testing Devices
      • Software Programs for Diabetes Monitoring
      • Artificial Pancreas
    • Therapeutics
      • Insulin
      • Insulin Delivery
      • Oral Hypoglycemic Agents
      • Cell Therapies
  • Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market, By Disease Type:
    • Type 2 Diabetes
    • Type 1 Diabetes
  • Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market, By Geography:
    • North America
      • By Category
        • Diagnosis and Monitoring
          • Blood Glucose Monitoring Devices
          • Other Testing Devices
          • Software Programs for Diabetes Monitoring
          • Artificial Pancreas
        • Therapeutics
          • Insulin
          • Insulin Delivery
          • Oral Hypoglycemic Agents
          • Cell Therapies
        • By Disease Type
          • Type 2 Diabetes
          • Type 1 Diabetes
        • By Country:
          • S.
          • Canada
    • Europe
      • By Category
        • Diagnosis and Monitoring
          • Blood Glucose Monitoring Devices
          • Other Testing Devices
          • Software Programs for Diabetes Monitoring
          • Artificial Pancreas
        • Therapeutics
          • Insulin
          • Insulin Delivery
          • Oral Hypoglycemic Agents
          • Cell Therapies
        • By Disease Type
          • Type 2 Diabetes
          • Type 1 Diabetes
        • By Country:
          • K.
          • Germany
          • Italy
          • France
          • Spain
          • Russia
          • Rest of Europe
    • Asia Pacific
      • By Category
        • Diagnosis and Monitoring
          • Blood Glucose Monitoring Devices
          • Other Testing Devices
          • Software Programs for Diabetes Monitoring
          • Artificial Pancreas
        • Therapeutics
          • Insulin
          • Insulin Delivery
          • Oral Hypoglycemic Agents
          • Cell Therapies
        • By Disease Type
          • Type 2 Diabetes
          • Type 1 Diabetes
        • By Country:
          • China
          • India
          • Japan
          • ASEAN
          • Australia
          • South Korea
          • Rest of Asia Pacific
    • Latin America
      • By Category
        • Diagnosis and Monitoring
          • Blood Glucose Monitoring Devices
          • Other Testing Devices
          • Software Programs for Diabetes Monitoring
          • Artificial Pancreas
        • Therapeutics
          • Insulin
          • Insulin Delivery
          • Oral Hypoglycemic Agents
          • Cell Therapies
        • By Disease Type
          • Type 2 Diabetes
          • Type 1 Diabetes
        • By Country:
          • Brazil
          • Mexico
          • Argentina
          • Rest of Latin America
    • Middle East:
      • By Category
        • Diagnosis and Monitoring
          • Blood Glucose Monitoring Devices
          • Other Testing Devices
          • Software Programs for Diabetes Monitoring
          • Artificial Pancreas
        • Therapeutics
          • Insulin
          • Insulin Delivery
          • Oral Hypoglycemic Agents
          • Cell Therapies
        • By Disease Type
          • Type 2 Diabetes
          • Type 1 Diabetes
        • By Country:
          • GCC
          • Israel
          • Rest of Middle East
    • Africa
      • By Category
        • Diagnosis and Monitoring
          • Blood Glucose Monitoring Devices
          • Other Testing Devices
          • Software Programs for Diabetes Monitoring
          • Artificial Pancreas
        • Therapeutics
          • Insulin
          • Insulin Delivery
          • Oral Hypoglycemic Agents
          • Cell Therapies
        • By Disease Type
          • Type 2 Diabetes
          • Type 1 Diabetes
        • By Country/Region:
          • Central Africa
          • South Africa
          • North Africa
  • Company Profiles
    • Abbott Laboratories *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Bristol-Myers Squibb
    • DexCom, Inc.
    • Eli Lilly and Company
    • Companion Medical
    • GlaxoSmithKline plc
    • Glenmark Pharmaceuticals
    • Johnson & Johnson
    • Lupin Ltd.
    • Hoffmann-La Roche AG
    • Sanofi

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Category
      • Market Snippet, By Disease Type
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
  4. Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market, By Category, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Diagnosis and Monitoring
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
        • Blood Glucose Monitoring Devices
        • Other Testing Devices
        • Software Programs for Diabetes Monitoring
        • Artificial Pancreas
    • Therapeutics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
        • Insulin
        • Insulin Delivery
        • Oral Hypoglycemic Agents
        • Cell Therapies
  5. Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market, By Disease Type, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Type 2 Diabetes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Type 1 Diabetes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
  6. Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market, By Regions, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  7. Competitive Landscape
    • Company Profiles
      • Abbott Laboratories
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Bristol-Myers Squibb
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • DexCom, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Companion Medical
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GlaxoSmithKline plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Glenmark Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Lupin Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • F. Hoffmann-La Roche AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sanofi
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 34 market data tables and 25 figures on “Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market – Global forecast to 2027.

Frequently Asked Questions

The global diabetes devices and drugs (diagnosis, monitoring, and therapeutics) market was valued at US$ 108,190.4 Mn in 2019 and is forecast to reach a value of US$ 231,909.8 Mn by 2027 at a CAGR of 10.0% between 2020 and 2027.
Therapeutics segment held the major market share in 2019 owing to increasing prevalence of diabetes, and treatment demand.
Major factor driving the growth of global diabetes devices and drugs (diagnosis, monitoring, and therapeutics) market during the forecast period include increasing prevalence of diabetes, and product launches.
Major factors hampering the growth of the diabetes devices and drugs (diagnosis, monitoring, and therapeutics) market during the forecast period constitutes of high treatment costs, and lack of awareness about diabetes management.
Some of the key players operating in the market are Abbott Laboratories, Bristol-Myers Squibb, DexCom, Inc., Eli Lilly and Company, Companion Medical, GlaxoSmithKline plc, Glenmark Pharmaceuticals, Johnson & Johnson, Lupin Ltd., F. Hoffmann-La Roche AG, and Sanofi.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner